Shilpa Gupta, MD, on Locally Advanced/Metastatic Urothelial Cancer: Phase III MAIN-CAV Trial
ASCO 2026
Shilpa Gupta, MD, of Taussig Cancer Institute, discusses findings from the phase III MAIN-CAV study (Alliance A032001) of maintenance cabozantinib and avelumab vs avelumab after first-line platinum-based chemotherapy in patients with locally advanced/metastatic urothelial cancer (Abstract 4514).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
In locally advanced and metastatic urothelial cancer, platinum based chemotherapy has been the standard of care for decades until recently when EV pembro showed that it was better than platinum in the frontline setting. Back in 2020, maintenance avelumab was approved for patients who did not progress on frontline platinum based chemotherapy and it improved survival compared to best supportive care. We wanted to build upon the avelumab backbone to see if we can help patients who don't have durable response and we designed this cooperative group trial to build on avelumab backbone with a VEGF TKI, cabozantinib or the MAIN-CAV trial was built on that. It was a very timely study at the time. We designed it to enroll 654 patients and randomized them to maintenance avelumab versus maintenance avelumab and cabozantinib, limiting the total duration of two years for each arm. Primary endpoint was overall survival and we hypothesized that we could build upon the median 21 month overall survival with the avelumab to 28 months with combination. And while the planned enrollment was for 654 patients, unfortunately we could not accrue the patient because of the new standard with EV and pembro. So we closed the trial after 68 patients were enrolled because EV pembro was approved in the US and we analyzed the patients enrolled and we found that you know 33 and 35 patients were enrolled in avelumab versus avelumab cabozantinib arm. Unfortunately we did not see differences in the progression-free survival or overall survival. But this is an underpowered study which was closed prematurely. So it's difficult to make that determination. But in the limited numbers we have, we did not see a difference and we did not see that cabozantinib even added to the response rate seen when avelumab. As far as toxicities were concerned, there were no new safety signals and there was more toxicity in the combination arm as expected with an IO and TKI. So at this time, we are working on the translational work for this study to guide future development around VEGF.
Related Videos
The ASCO Post Staff
John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in patients newly diagnosed with diffuse large B-cell lymphoma (Abstract LBA7000).
Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580).
The ASCO Post Staff
Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, reviews the results of the RAMPART study, a phase II, multicenter, single-arm clinical trial evaluating response-adapted definitive radiotherapy in combination with cemiplimab-rwlc for locally advanced, unresectable cutaneous squamous cell carcinoma (CSCC) (Abstract 9506).
The ASCO Post Staff
Krishnan R. Patel, MD, of the National Cancer Institute, discusses a combined analysis of the NRG/RTOG 9202, 9413, 9902, and 0521 trials that looked at using clinico-transcriptomic risk stratification to guide abiraterone treatment intensification among patients with high-risk prostate cancer (Abstract 5000).
The ASCO Post Staff
Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute, and Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, describe results from the phase III RASolute 302 trial, which evaluated the RAS(ON) muliselective inhibitor daraxonrasib in previously treated patients with metastatic pancreatic adenocarcinoma (Abstract LBA5).